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Abstract
Background
Hepatitis C virus (HCV) is the most common viral infection among injecting drug users
worldwide. We aimed to assess HCV antibody prevalence and associated risk factors
among clients in the Chinese national methadone maintenance treatment (MMT) program.
Methods
Data from 296,209 clients who enrolled in the national MMT program between March 2004
and December 2012 were analyzed to assess HCV antibody prevalence, associated risk
factors, and geographical distribution.
Results
Anti-HCV screening was positive for 54.6% of clients upon MMT entry between 2004 and
2012. HCV antibody prevalence at entry declined from 66.8% in 2005 to 45.9% in 2012.
The most significant predictors of HCV seropositivity were injecting drug use (adjusted odds
ratio [AOR]: 8.34, 95% confidence interval [CI]: 8.17–8.52, p<0.0001) and a history of drug
use9 years (AOR: 2.01, 95% CI: 1.96–2.06, p<0.0001). Being female, of Uyghur or
Zhuang ethnicity, and unmarried were identified as demographic risk factors (all p-val-
ues<0.0001). Of the 28 provincial-level divisions included in the study, we found that 5 divi-
sions had HCV antibody prevalence above 70% and 20 divisions above 50%. The HCV
screening rate within 6 months after MMT entry greatly increased from 30.4% in 2004 to
93.1% in 2012.
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Conclusions
The current HCV antibody prevalence remains alarmingly high among MMT clients through-
out most provincial-level divisions in China, particularly among injecting drug users and
females. A comprehensive prevention strategy is needed to control the HCV epidemic
among MMT clients in China.
Introduction
Hepatitis C virus (HCV) is a leading cause of chronic liver disease, including hepatitis, cirrho-
sis, and hepatocellular carcinoma [1–4]. Estimates of the HCV antibody prevalence among the
Chinese general population have varied from 0.43% to 2.2%, corresponding to a range of 6 mil-
lion to 30 million people [5–7]. While HCV transmission can occur via a variety of modes, the
most common route is injecting drug use [3], and HCV is the most common viral infection
among injecting drug users (IDU) worldwide[8, 9]. China’s drug user (DU) population has
been estimated to be as high as 3.5 million, most of whom are opioid users and use drugs by
injecting [10]. Thus, it is not surprising that HCV antibody prevalence among DU in China is
thought to be very high, ranging from 15.6% to 98.7% in different geographical areas [11].
Meta-analyses have estimated a national HCV antibody prevalence of 67.0% among IDU and
60.1% among DU in methadone maintenance treatment (MMT) [12, 13].
Although implemented in response to the rapidly growing HIV/AIDS epidemic, China’s
National MMT Program [14] also screens clients for anti-HCV upon enrollment and refers
those identified as HCV seropositive to appropriate healthcare facilities. The MMT program
started with 8 pilot sites in 2004 and has since rapidly expanded to become the world’s largest
opioid-substitution treatment network [15]. By the end of 2012, there were 756 MMT clinics in
China that had served about 380,000 clients cumulatively [16]. The numbers of MMT clinics
vary from 1 to 71 among provincial-level divisions (defined as provinces, autonomous regions,
and municipalities). Counties or districts where there are over 500 registered opioid users must
have at least one established MMT clinic.
The national HCV antibody prevalence among Chinese MMT clients has not been previ-
ously reported. Given the high transmissibility of HCV among IDU, the overall HCV antibody
prevalence among MMT clients is thought to be consistently high nationwide, particularly in
provincial-level subdivisions with high rates of injecting drug use. We aim to assess the HCV
antibody prevalence, risk factors, and geographical distribution among China’s MMT client
population. The secondary aim is to assess the proportion of MMT clients who have accessed
HCV antibody testing.
Materials and Methods
Study design and participants
The study cohort comprised all drug users enrolling in the national MMT program between
March 2004 and December 2012. Participants were excluded if they could not be tracked by a
unique client identification number (e.g., if the same identification number was incorrectly
assigned to multiple clients or if the number contained errors). For clients who had dropped out
of MMT and re-entered at a subsequent date, we restricted our analysis to the earliest enroll-
ment record. Current guidelines state that all new clients should be screened for HCV antibody
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upon enrollment and that HCV-negative clients should be tested once every 12 months. Anti-
body-based testing is provided to all clients free of charge.
Data collection
Data from this study were abstracted from the national MMT data system, which is one of
eight subsystems of the national unified data collection system, the China National HIV/AIDS
Comprehensive Response Information Management System (CRIMS). CRIMS is managed by
the National Center for AIDS/STD Control and Prevention (NCAIDS) of the Chinese Center
for Disease Control and Prevention (Chinese CDC) and has been described in detail elsewhere
[17]. In brief, the MMT data system is updated daily with service records from each clinic.
Local clinics complete baseline assessments at the initial visit to collect information on demo-
graphics, medical history, and drug use behavior. From this database, the following data were
collected for clients>16 years of age for this study: sex, date of birth, ethnicity, education level,
marital status, occupation, years of drug use, and injecting and needle sharing history, HIV ser-
ostatus, HCV serostatus and test dates.
Statistical Analyses
We tabulated estimates of provincial- and national-level HCV antibody prevalence. The pri-
mary data analyses were limited to clients>16 years old who had a HCV test result at baseline,
which we defined as within 6 months after entry. A binomial distribution, which was normally
approximated, was assumed for 95% confidence intervals (CI) for prevalence estimates. Unad-
justed odds ratios (OR) were generated by a logistic regression model for each covariate. A test
for trend was used to assess the association between years of past drug use and HCV antibody
prevalence. Adjusted odds ratios (AOR) were estimated from a multivariable logistic regression
model. Variables with p<0.01 under univariate regression analysis were included in the multi-
variable model as potential confounders. All statistical analyses were performed using SAS soft-
ware (Version, 9.3, SAS Institute Inc.,USA). All reported CIs are 95%, and p-values are two-
sided.
Ethical approval
This study was reviewed and approved by the Institutional Review Board of NCAIDS. As all
data included here were collected during the regular administration of China’s National MMT
Program, and all participants in this program provided informed consent at the time of enroll-
ment, no further study-specific informed consent was sought. Data from participants younger
than 16 were only used to calculate provincial- and national-level HCV screening coverage and
HCV antibody prevalence and were otherwise excluded.
Results
Study Cohort
The development of the study cohort is presented in Fig 1. Between March 2004 and December
2012, 379,552 drug users had been enrolled into MMT, and 342,443 MMT clients (90.2%) had
received a HCV antibody test at least once. Among these clients, 46,234 (13.5%) were excluded
from the primary study analyses because their first HCV test result did not occur within 6
months after entry. The final study cohort was composed of 296,209 participants.
HCV antibody prevalence at baseline. In the initial year of the MMT program in 2004,
only 1,438 clients were enrolled. The number of clients enrolled quadrupled in the second year
and again in the third year. The peak of newly enrolled clients was 76,528 individuals in 2008,
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Fig 1. Development of the study cohort.
doi:10.1371/journal.pone.0147922.g001
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which then decreased from 66,871 in 2009 and to 40,596 in 2012 (Table 1). The proportion of
self-reported IDU was stable at 81% in the first three years (2004–2006), but decreased to
76.1% in 2007 and reached a low of 56.0% in 2012. The proportion of clients who obtained
HCV testing was less than one-third in 2004 (30.4%) and 2005 (27.8%) and then increased
from 59.1% in 2006 and to 93.1% in 2012. The HCV antibody prevalence among overall clients
enrolled in 2004 was 34.6%. The HCV antibody prevalence sharply increased to 66.8% in the
second year of 2005 but has shown steady annual declines up to the last year of the study in
2012 (45.9%). The HCV antibody prevalence among self-reported IDU peaked at 74.1% in the
second year and was stable from 2006–2011 at 70–74% before falling slightly to 68.9% in 2012.
Geographical Distribution
The utilization of MMT and the HCV antibody prevalence varied significantly by provincial-
level division (Table 2). Five provincial-level divisions had more than 30,000 MMT clients, and
three had less than 1,000. Eight divisions had more than 10,000 HCV antibody-positive MMT
clients.
The baseline HCV antibody prevalence ranged from a low of 5.6% in Shanxi province to a
high of 78.1% in Tianjin municipality. The distributions of HCV antibody prevalence and pro-
portion of self-reported IDU nationwide are presented in Fig 2. Data were not available from
some provincial-level divisions because the MMT program has not yet been established in
those areas.
Table 1. Self-reported injecting drug use (IDU), HCV antibody testing, and HCV antibody prevalence among newly enrolled MMT clients by year,
2004–2012.
2004 2005 2006 2007 2008 2009 2010 2011 2012 Total
Clients
newly
enrolled into
MMT
1438 5440 28747 58783 76528 66871 52521 48628 40596 379552
Self-
reported
IDU (%)
81.2 81.1 81.6 76.1 72.3 66.6 60.6 59.3 56.0 67.7
HCV testing
within 6
months after
enrollment
(%)
30.4 27.8 59.1 68.7 75.8 79.4 83.6 90.7 93.1 78.0
Baseline
HCV
antibody
prevalence
% (95% CI)
34.6
(30.1–39.0)
66.8
(64.4–69.2)
64.8
(64.1–65.5)
61.7
(61.2–62.2)
59.5
(59.1–59.9)
54.9
(54.5–55.3)
49.9
(49.4–50.3)
49.2
(48.8–49.7)
45.9
(45.4–46.4)
54.6
(54.4–54.8)
HCV
antibody
prevalence
among
clients self-
reporting
IDU* %
(95% CI)
37.4
(32.6–42.3)
74.1
(71.7–76.5)
72.6
(71.9–73.4)
72.9
(72.4–73.4)
73.2
(72.8–73.6)
71.9
(71.4–72.4)
70.5
(69.9–71.0)
70.9
(70.3–71.4)
68.9
(68.3–69.5)
71.7
(71.5–71.9)
CI: confidence interval
*Among clients with baseline HCV antibody test results.
doi:10.1371/journal.pone.0147922.t001
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The demographic and drug use characteristics of the cohort are summarized in Table 3. The
overall HCV antibody prevalence upon entry among the 296,209 MMT clients with baseline
test results was 54.6% (95% CI: 54.5–54.8). Most clients were male (84.9%), middle-aged (30–
44 years 64.6%), Han Chinese (85.7%), educated beyond middle school (79.2%), unmarried
(52.3%), and unemployed (66.3%). The HIV antibody prevalence was 5.8%. More than half
(51.1%) reported having used drugs for 9 or more years prior to enrollment in MMT. While
two-thirds of clients self-reported drug use through injecting (66.8%), most reported that they
had never shared needles (87.6%). HCV antibody prevalence was highest among HIV-positive
Table 2. Self-reported injecting drug use (IDU), HCV antibody testing, and HCV antibody prevalence among newly enrolled MMT clients by provin-
cial-level division, 2004–2012.
Division Number of MMT clients Self-reported IDU (%) Received anti-HCV test at least once (%)† HCV seropositivity (%)‡
Anhui 3494 2603 (74.5) 3281 (93.9) 1746 (56.6)
Beijing 3264 2578 (79.0) 3065 (93.9) 1695 (63.4)
Chongqing 21894 18940 (86.5) 21016 (96.0) 14166 (74.5)
Fujian 8179 5670 (69.3) 7657 (93.6) 3773 (52.4)
Gansu 16178 3122 (19.3) 15433 (95.4) 2176 (15.3)
Guangdong 28656 23839 (83.2) 25705 (89.7) 16535 (69.5)
Guangxi 31013 25405 (81.9) 29060 (93.7) 18174 (68.9)
Guizhou 37514 18703 (49.9) 32846 (87.5) 12257 (45.7)
Hainan 13557 8754 (70.3) 11175 (82.4) 3883 (40.4)
Hebei 378 343 (90.7) 369 (97.6) 269 (73.9)
Heilongjiang* - - - -
Henan 6209 891 (14.4) 5888 (94.8) 403 (7.2)
Hubei 21725 17493 (80.6) 19835 (91.3) 11588 (68.3)
Hunan 31205 24109 (77.3) 27897 (89.4) 15140 (60.2)
Inner Mongolia 4146 1934 (46.6) 3954 (95.4) 1241 (32.5)
Jiangsu 8764 7440 (84.9) 8546 (97.5) 5851 (71.7)
Jiangxi 5119 4458 (87.1) 4559 (89.1) 2692 (69.2)
Jilin 323 306 (94.7) 275 (85.1) 141 (65.0)
Liaoning* - - - -
Ningxia 5012 1822 (36.4) 4543 (90.6) 1038 (26.4)
Qinghai 1266 846 (66.8) 1225 (96.8) 783 (67.5)
Shandong 67 59 (88.1) 36 (53.7) 21 (72.4)
Shanghai 6188 4722 (76.3) 5365 (86.7) 2966 (66.4)
Shannxi 21171 13140 (62.1) 19391 (91.6) 8555 (50.0)
Shanxi 4583 365 (8.0) 4103 (89.5) 212 (5.6)
Sichuan 34839 23434 (67.3) 29610 (85.0) 11227 (50.2)
Tianjin 1411 1308 (92.7) 1389 (98.4) 1072 (78.1)
Tibet* - - - -
Xinjiang 13104 11181 (85.3) 11886 (90.7) 7019 (68.5)
Yunnan 35427 23663 (66.8) 31167 (88.0) 12541 (54.3)
Zhejiang 14866 7853 (52.8) 13168 (88.6) 4523 (38.7)
Total 379595 254981 (67.7) 342443 (90.2) 161687 (54.6)
*Division did not have an MMT clinic by the end of 2012.
† Based on MMT clients who received at least one HCV antibody test (baseline or follow-up test).
‡Based on MMT clients with baseline HCV antibody test results.
doi:10.1371/journal.pone.0147922.t002
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Fig 2. The geographical distribution of (A) HCV antibody prevalence and (B) proportion of injecting
drug use among MMT clients with baseline HCV test results in China.
doi:10.1371/journal.pone.0147922.g002
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Table 3. HCV antibody prevalence and risk factors amongMMT clients with baseline HCV test results in China, 2004–2012.
Participants, N
(%)
HCV
Cases, n
Prevalence, %
(95% CI)
Unadjusted OR,
(95% CI)
P-value Adjusted OR,
(95% CI)
P-value
Demographic
characteristics
Gender
Male 251599 (84.9) 135395 53.8 (53.6–54.0) 1.0 1.0
Female 44610 (15.1) 26292 58.9 (58.5–59.4) 1.23 (1.21–1.26) <0.0001 1.39 (1.36–1.43) <0.0001
Age (years)
16–29 71881 (24.3) 35664 49.6 (49.2–50.0) 1.00 1.00
30–44 191480 (64.6) 109550 57.2 (57.0–57.4) 1.36 (1.34–1.38) <0.0001 1.35 (1.31–1.38) <0.0001
45 32848 (11.1) 16473 50.1 (49.6–50.7) 1.02 (1.00–1.05) <0.0001 1.28 (1.24–1.33) <0.0001
Ethnicity
Han 253947 (85.7) 140492 55.3 (55.1–55.5) 1.00 1.00
Hui 7529 (2.5) 3089 41.0 (39.9–42.1) 0.56 (0.54–0.59) <0.0001 0.77 (0.73–0.82) <0.0001
Uyghur 7086 (2.4) 4900 69.1 (68.1–70.2) 1.81 (1.72–1.90) <0.0001 1.34 (1.26–1.42) <0.0001
Zhuang 8976 (3.0) 5435 60.6 (59.5–61.6) 1.24 (1.19–1.29) <0.0001 1.29 (1.22–1.36) <0.0001
Other 18631 (6.3) 7745 41.6 (40.9–42.3) 0.58 (0.56–0.59) <0.0001 0.78 (0.75–0.81) <0.0001
Missing data 40 (0) 26
Education level
 Primary school 61629 (20.8) 32446 52.6 (52.3–53.0) 1.00 1.00
Middle school 170559 (57.6) 94927 55.7 (55.4–55.9) 1.13 (1.11–1.15) <0.0001 1.02 (1.00–1.05) <0.0001
 High school 63993 (21.6) 34294 53.6 (53.2–54.0) 1.04 (1.02–1.06) 0.0146 0.95 (0.92–0.98) <0.0001
Missing data 28 (0) 8
Marital Status
Married 140732 (47.5) 67830 48.2 (47.9–48.5) 1.00 1.00
Unmarried 155009 (52.3) 93600 60.4 (60.1–60.6) 1.64 (1.61–1.66) <0.0001 1.25 (1.23–1.28) <0.0001
Missing data 468 (0.2) 257
Occupation
Employed 99927 (33.7) 47516 47.6 (47.2–47.9) 1.00 1.00
Unemployed 196252 (66.3) 114150 58.2 (58.0–58.4) 1.53 (1.51–1.56) <0.0001 1.12 (1.11–1.15) <0.0001
Missing data 30 (0) 21
HIV serostatus
Negative 254170 (85.8) 133180 52.4 (52.2–52.6) 1.00 1.00
Positive 17200 (5.8) 13700 79.7 (79.1–80.3) 3.56 (3.42–3.70) <0.0001 1.74 (1.67–1.82) <0.0001
Missing data 24839 (8.4) 14806
Drug use history
characteristics
Duration (years)
0–2 55874 (18.9) 18611 33.3 (32.9–33.7) 1.00 1.00
3–5 44525 (15.0) 20812 46.7 (46.3–47.2) 1.76 (1.71–1.80) <0.0001 1.31 (1.27–1.35) <0.0001
6–8 43063 (14.5) 24801 57.6 (57.1–58.1) 2.72 (2.65–2.79) <0.0001 1.67 (1.62–1.72) <0.0001
 9 151408 (51.1) 96823 63.9 (63.7–64.2) 3.55 (3.48–3.63) <0.0001 2.01 (1.96–2.06) <0.0001
Missing data 1339 (0.5) 640 47.8 (45.1–50.5)
Injecting drug use
No 96824 (32.7) 19333 20.0 (19.7–20.2) 1.00 1.00
Yes 197832 (66.8) 141810 71.7 (71.5–71.9) 10.15 (9.96–10.34) <0.0001 8.34 (8.17–8.52) <0.0001
Missing data 1553 (0.5) 544
Ever shared needles
No 259459 (87.6) 132830 51.2 (51.0–51.4) 1.00 1.00
(Continued)
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clients (79.7%, 95% CI: 79.1–80.3) and those who had reported injecting drugs (71.7%, 95% CI:
71.5–71.9) or sharing needles (78.5%, 95% CI: 78.1–78.9).
Risk factors associated with HCV infection
Risk factors associated with being HCV antibody positive are shown in Table 3. The risk was
higher for participants who were female (AOR: 1.39, 95% CI: 1.36–1.43, p<0.0001), over 30
years (30–44 years AOR: 1.35, 95% CI: 1.31–1.38, p<0.0001; age group45 years AOR: 1.28,
95% CI: 1.24–1.33, p<0.0001), of Uyghur or Zhuang ethnicity (Uyghur AOR: 1.34, 95% CI:
1.29–1.42, p<0.0001; Zhuang AOR: 1.29, 95% CI: 1.22–1.36, p<0.0001), having attained a
middle school education (AOR: 1.02, 95% CI: 1.00–1.05, p<0.0001 compared to primary
school), unmarried (AOR: 1.25, 95% CI: 1.23–1.28, p<0.0001), unemployed (AOR: 1.12, 95%
CI: 1.11–1.15, p<0.0001), HIV-positive (AOR: 1.74, 95% CI: 1.67–1.82, p<0.0001), had a lon-
ger history of drug use (9 years AOR: 2.01, 95% CI: 1.96–2.06; 6–8 years AOR: 1.67, 95% CI:
1.62–1.72; 3–5 years AOR: 1.31, 95% CI:1.27–1.35, all p<0.0001and trend test p<0.0001), had
reported injecting drug use (AOR: 8.34, 95% CI: 8.17–8.52, p<0.0001) and had ever shared
needles (AOR: 1.52, 95% CI: 1.48–1.57, p<0.0001).
Discussion
China’s national MMT program was established as part of an overarching strategy to stem the
HIV epidemic. The national MMT program provides regular anti-HCV testing, and the HCV
antibody prevalence has not been previously described. Although the HIV epidemic is largely
concentrated in six provincial-level divisions, HCV antibody prevalence among MMT clients
was presumed to be high nationwide due to its high transmissibility, particularly through
injecting drug use. By utilizing the National MMT Program database, we presented an over-
view of the prevalence, risk factors, and geographical distribution of anti-HCV seropositivity in
the Chinese MMT client population from the program’s inception in 2004 through 2012.
The primary strength of this observational study is the large sample size and access to the
National MMT program database, which covers nearly all geographical regions in China. The
length of the study period covers the entire existence of the Chinese MMT program from 2004
to 2012, which allows for monitoring of HCV antibody prevalence trends among newly
enrolled MMT clients. Due to the large sample size and high coverage of areas, the results of
this study allow for a comprehensive assessment of HCV epidemiology among DUs in China.
HCV antibody prevalence
From 2004 to 2012, the overall HCV antibody prevalence for all MMT clients at enrollment
was 54.6%. This is lower than the prevalence estimates from recent meta-analyses of 67.0%
among IDUs and 60.1% among DUs in MMT [12, 13]. Drug injecting was reported by 66.8%
of clients, and 12.4% reported needle sharing. The HCV antibody prevalence among IDUs in
Table 3. (Continued)
Participants, N
(%)
HCV
Cases, n
Prevalence, %
(95% CI)
Unadjusted OR,
(95% CI)
P-value Adjusted OR,
(95% CI)
P-value
Yes 36747 (12.4) 28854 78.5 (78.1–78.9) 3.49 (3.40–3.58) <0.0001 1.52 (1.48–1.57) <0.0001
Missing data 3 (0) 3
Total 296209 161687 54.6 (54.5–54.8)
CI: confidence interval, OR: odds ratio.
doi:10.1371/journal.pone.0147922.t003
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MMT in our cohort was higher (71.7%) than previous estimates of 61.4% and 66.97%, although
it is worth noting that their studies focused on IDUs regardless of MMT enrollment [18, 19].
The HCV antibody prevalence in the Chinese MMT program is similar to estimates
reported in MMT clinics in other countries. Most studies of HCV antibody prevalence among
MMT clients in other countries (including the United States, Switzerland, and Australia) were
limited to individual cities or MMT clinics [20–24]. These studies showed variance in HCV
antibody prevalence among MMT clients ranging from 58% to 87%. Direct comparisons
between sites and studies are unreliable due to the differences in study cohort profiles, particu-
larly related to the percentages of IDU and non-injecting DU.
In China, the HCV antibody prevalence of clients upon MMT entry has declined each year
from 2005 (66.8%) to 2012 (45.9%). (An exception is the first year of the MMT program in
2004, which reported a rate of 34.6%; this may be due to the very low HCV antibody screening
coverage and unreliable lab results during the initial pilot period of the MMT program). It may
be that the decreasing annual HCV antibody prevalence results is driven by the decreasing pro-
portions of IDUs among newly enrolled MMT clients. Concurrently, the HCV antibody testing
coverage at baseline has greatly increased from 30.4% in 2004 to 93.1% in 2012, which indicates
a remarkable improvement in MMT health services and linkage to anti-HCV testing.
Risk Factors
The factors most strongly associated with HCV infection were related to drug use history,
which has been addressed in depth in the literature. The prevalence of HCV increased with lon-
ger histories of drug use [3, 25–27]. HCV infection was also much more likely to be present
among IDUs and HIV-positive clients [3, 8, 19, 26].
One factor that has not been addressed thoroughly is the difference in anti-HCV prevalence
by sex. Women had a higher prevalence of 58.9% compared to a prevalence of 53.8% for men.
Other studies on HCV antibody and DU in China in the English and Chinese research literature
were not at a consensus on sex as a risk factor [11, 18, 26–29]. In the national general popula-
tion, there is no significant difference in HCV antibody prevalence between sex [30]. However,
another study also suggests that sexual transmission of HCVmay be more efficient in females
[24]. Future research should address sex as a risk factor for HCV antibody positivity.
Geographical Distribution
Our findings indicate that the HCV antibody prevalence among MMT clients is alarmingly
high throughout China. Of the 28 provincial-level divisions included in our study, 20 reported
rates above 50%, including 5 divisions with prevalence above 70%. HCV antibody prevalence
showed extremely wide variations between divisions. We believe that these differences can be
attributed in part to the different distribution of IDU in regions. In the provincial-level divi-
sions with the two lowest HCV antibody prevalence, Henan and Shanxi, we found that these
two provinces had very low percentages of clients who reported having injected drugs (Henan:
14.0%; Shanxi: 8.1%) compared to the national percentage (66.8%). Tianjin, the provincial-
level division with highest rate of HCV antibody prevalence at 78.1%, also had a remarkably
high percentage of IDUs (92.7%). Regions with high proportions of IDUs should be focal
regions for controlling the HCV epidemic. Of all provincial-level divisions that have imple-
mented MMT, eight had more than 10,000 HCV antibody positive MMT clients.
Comparison to the HIV Epidemic
The Chinese MMT program was originally implemented as a response to the emerging HIV epi-
demic[14]. Historically and presently, the HIV epidemic in China has been largely concentrated
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in 6 provincial-level divisions: Yunnan, Guangxi, Henan, Sichuan, Xinjiang and Guangdong
[31]. With the exception of Henan, these divisions lie along major drug trafficking routes and
are the top five are as for HCV and HIV co-infection. While MMT has contributed to slowing
the spread of HIV, MMT without other harm reduction strategies has not been as effective for
controlling the HCV epidemic [32]. This situation is not unique to China; studies from many
countries have noted that HCV has a higher transmission probability than HIV [25, 33, 34].
One example is Hong Kong, where under a long-established MMT program with over 90% cov-
erage, HIV antibody prevalence was 0.3% and HCV antibody prevalence was 85% [23].
Recommendations
Because many IDUs first begin drug use through non-injecting methods [35], implementing
outreach efforts to this population of non-injecting DUs can potentially prevent transition to
drug injecting [33]. Data showed a 71.7% HCV antibody prevalence for IDUs compared to
20.0% for non-injecting DUs. This HCV antibody prevalence for non-injecting DUs is compa-
rable to other studies reporting rates of 2.3% to 35.3% [19, 36], and the difference in prevalence
between IDUs and non-injecting DUs is similar to results from other studies [19, 33]. In our
data, the low proportion of IDU in Henan and Shanxi is strongly correlated with the remark-
ably low HCV antibody prevalence in these two provinces. We recommend further investiga-
tion on what distinguishes these two provinces in this regard from the rest of the country.
Emphasizing routine testing for HCV antibody is critically important for MMT clients
because a positive serostatus has clinical implications. Low levels of HCV knowledge has been
cited as a barrier to antibody testing and treatment in China and abroad [37, 38]. Clients who
were positive for HCV antibody have been shown to need significantly higher dosages of meth-
adone [24]. Researchers have recommended that it would be beneficial for anti-HCV positive
clients to receive treatment of HCV infection at methadone clinics[39], echoing a similar sug-
gestion regarding antiretroviral therapy for HIV. Cost is a significant barrier to clients because
unlike ART, neither methadone nor HCV treatment is free in China. MMT services costs up to
10 RMB per day (~$1.60 USD).
Finally, we recommend further expansion of China’s needle and syringe exchange programs
to supplement MMT. Multi-component harm reduction strategies that include MMT and nee-
dle and syringe exchange programs have shown effectiveness is reducing the risk of HCV sero-
conversion up to 75–80% [32, 40]. In 2011, China had 913 needle and syringe exchange sites,
which distributed 12 million needles and syringes to over 60,000 IDUs [16]. However, it is esti-
mated that only about 2% of IDUs in China have been able to access needle exchange programs
so far [41].
Limitations
While our study relied on HCV antibody tests to determine infection status, it is notable that
spontaneous resolution or viral clearance occurs in 15–20% of individuals, which varies by race
and sex [42, 43]. Our study is limited to describing HCV antibody prevalence, instead of clini-
cal presentation of active HCV. We were also limited to describing the HCV antibody preva-
lence upon entry to MMT, which is not directly reflective of all MMT clients. We could only
include MMT clients who had at least one anti-HCV test result within 6 months in the primary
analysis; due to the high early attrition rate in MMT, many clients drop-out without receiving
HCV antibody testing [44, 45]. We excluded 13.5% of cases due to a lack of HCV antibody test-
ing within 6 months of entry. Most excluded participants had enrolled in MMT at early stages
of the program when anti-HCV testing rates were comparatively low. Compared with MMT
clients without baseline HCV test results, MMT clients with a known baseline serostatus have a
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slightly lower proportion of self-reported IDU and needle sharing, and have a longer history of
drug use. Also, some clients may acquire HCV during the course of MMT due to ongoing drug
use [46]. As these four factors increase the risk for HCV infection, the HCV antibody preva-
lence of all MMT clients may be slightly higher than the prevalence among MMT clients who
were tested at entry. However, we believe that these differences would not have a large impact
on the final results nor would it alter our conclusions. We also acknowledge that the accuracy
and reliability of data is dependent on the performance of local staff from clinics located
around the country, including in resource-limited areas. Due to the different brands of anti-
HCV tests, this may also have caused slight variations between different MMT clinics. We
attempted to reduce the role of confounding variables by using a multivariable analysis model
but as in all observational studies, there still remains a residual risk of confounding. Finally,
due to the extremely large number of cases included in the analysis, we acknowledge that a rela-
tively slight difference between groups can create a statistically significant estimate.
Our study concludes that the HCV antibody prevalence among MMT clients has reached
alarmingly high rates in many areas within China, which is reflective of the high transmissibil-
ity of HCV. Routine antibody screening, treatment options that address drug use, HCV infec-
tion, and potential HIV/HCV co-infection, and continued expansion of MMT and needle and
syringe exchange programs are critical components of a comprehensive national control and
prevention strategy.
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